MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Elenco Azioni・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Chiusa

SettoreSettore sanitario

0.26 -3.7

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.26

Massimo

0.27

Metriche Chiave
By Trading Economics
Entrata	-2.5M -37M
Vendite	14M 14M
EPS	-0.111
Margine di Profitto	-262.996
Dipendenti	142
EBITDA	10M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+2207.69% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-18M 106M
Apertura precedente	3.96
Chiusura precedente	0.26

Notizie sul Sentiment di mercato

By Acuity

43%

57%

115 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

0.5207 / 0.7223 Supporto e resistenza

Sangamo Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 apr 2026, 23:48 UTC

Principali Notizie su Eventi

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 apr 2026, 23:36 UTC

Principali Notizie su Eventi

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 apr 2026, 22:47 UTC

Principali Notizie su Eventi

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 apr 2026, 21:14 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 apr 2026, 21:14 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 apr 2026, 23:49 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 apr 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 apr 2026, 23:38 UTC

Principali Notizie su Eventi

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 apr 2026, 23:36 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 apr 2026, 23:12 UTC

Principali Notizie su Eventi

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 apr 2026, 23:10 UTC

Principali Notizie su Eventi

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 apr 2026, 23:09 UTC

Principali Notizie su Eventi

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 apr 2026, 23:08 UTC

Principali Notizie su Eventi

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 apr 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 apr 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 apr 2026, 20:03 UTC

Principali Notizie su Eventi

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 apr 2026, 20:03 UTC

Principali Notizie su Eventi

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 apr 2026, 20:03 UTC

Principali Notizie su Eventi

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 apr 2026, 20:03 UTC

Principali Notizie su Eventi

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 apr 2026, 01:00 UTC

Principali Notizie su Eventi

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Utili

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Discorsi di Mercato

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Utili

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Utili

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Utili

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Sangamo Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

2207.69% in crescita

Previsioni per 12 mesi

Media 6 USD 2207.69%

Alto 10 USD

Basso 2 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.5207 / 0.7223Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

115 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.